CervoMed Inc.
CRVO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.15 | -0.02 | -0.06 |
| FCF Yield | -11.57% | -4.89% | -39.53% | -6.37% |
| EV / EBITDA | -7.25 | -13.04 | -1.57 | -22.11 |
| Quality | ||||
| ROIC | -18.26% | -15.31% | -18.30% | -11.82% |
| Gross Margin | 0.00% | -152.34% | -227.78% | -164.19% |
| Cash Conversion Ratio | 0.84 | 1.04 | 0.80 | 1.20 |
| Growth | ||||
| Revenue 3-Year CAGR | 685,715.89% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -67.29% | 51.63% | 0.52% | -267.61% |
| Safety | ||||
| Net Debt / EBITDA | 1.26 | 1.98 | 1.24 | 1.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 120.89 | 41.88 | 74.64 | -6.75 |